Real companies with freely usable public data: official annual reports of European listed companies (ESEF), SEC accounts and ECB exchange rates. No share prices, so there is no market capitalisation, P/E or EV/EBITDA.
Company sheet · analysis as of 21/10/2026
Abbott Laboratories
Shareholder score without valuation
37
Coverage 83 %
Credit score
57
Coverage 100 %
Alerts
0
Screens passed: 0 of 1
Shareholder view
| Factor | Value | Compared with | Percentile | Weight | Contribution |
|---|---|---|---|---|---|
| ROE | 12.1 % | Sector (6 companies) | 42 | 17 % | 8.3 |
| ROIC | 7.2 % | Sector (7 companies) | 36 | 17 % | 7.1 |
| Gross margin | No data | — | — | 17 % | — |
| LTM gross profit: missing “Gross profit” for FY 31/12/2025, Q1 31/03/2026, Q1 31/03/2025 | |||||
| EBITDA margin | 24.1 % | Sector (7 companies) | 21 | 17 % | 4.3 |
| Cash conversion | 117.6 % | Sector (7 companies) | 50 | 17 % | 10.0 |
| Revenue growth | 6.6 % | Sector (7 companies) | 36 | 17 % | 7.1 |
Formulas and inputs
ROE: LTM attributable net income / Attributable equity at period end
- LTM attributable net income
- 6,276.0
- Attributable equity
- 52,061.0
ROIC: LTM EBIT × (1 − notional tax rate) / (Total equity + Financial debt − Cash)
- LTM EBIT
- 7,705.0
- Total equity
- 52,701.0
- Financial debt
- 34,047.0
- Cash and equivalents
- 6,803.0
- Notional tax rate
- 0.2500
Gross margin: LTM gross profit / LTM revenue
EBITDA margin: LTM EBITDA / LTM revenue
- LTM EBITDA
- 10,868.0
- LTM revenue
- 45,134.0
Cash conversion: (LTM operating cash flow − LTM capex) / LTM net income attributable
- LTM operating cash flow
- 9,464.0
- LTM capital expenditure (capex)
- 2,086.0
- LTM attributable net income
- 6,276.0
Revenue growth: LTM revenue / LTM revenue a year earlier − 1
- LTM revenue
- 45,134.0
- Prior-year LTM revenue
- 42,344.0
Amounts in euros
| Market capitalisation | No data |
| Enterprise value (EV) | No data |
| LTM revenue | 38,938 M EUR |
| LTM EBITDA | 9,376 M EUR |
| Net debt | 23,695 M EUR |
Creditor view
| Factor | Value | Compared with | Percentile | Weight | Contribution |
|---|---|---|---|---|---|
| Net debt/EBITDA | 2.5x | Sector (7 companies) | 50 | 33 % | 16.7 |
| Interest coverage | 20.3x | Sector (7 companies) | 79 | 33 % | 26.2 |
| Debt/equity | 0.6x | Sector (6 companies) | 42 | 33 % | 13.9 |
Formulas and inputs
Net debt/EBITDA: (Financial debt − Cash) / LTM EBITDA
- Financial debt
- 34,047.0
- Cash and equivalents
- 6,803.0
- LTM EBITDA
- 10,868.0
Interest coverage: LTM EBITDA / LTM interest expense
- LTM EBITDA
- 10,868.0
- LTM interest expense
- 536.00
Debt/equity: Financial debt / Total equity
- Financial debt
- 34,047.0
- Total equity
- 52,701.0
Outstanding bonds
The loaded data contain no outstanding bonds of this company.
Alerts
No alerts in this run.
Screens
| Screen | Result | Conditions |
|---|---|---|
| Moderate leverage | Fails | Net debt/EBITDA ≤ 2.5x: value: 2.5x Interest coverage ≥ 5.0x: value: 20.3x |
Annual history (millions of USD)
| 2023 FY 31/12/2023 | 2024 FY 31/12/2024 | 2025 FY 31/12/2025 | |
|---|---|---|---|
| Revenue | 40,109 | 41,950 | 44,328 |
| EBITDA | 9,721 | 10,043 | 11,169 |
| Attributable net income | 5,723 | 13,402 | 6,524 |
| Free cash flow | 5,059 | 6,351 | 7,395 |
| Net debt | 7,783 | 6,509 | 4,407 |
Each fiscal year is labelled with the calendar year in which most of its months fall.
The scores summarise metrics compared with similar companies, and the alerts point to specific facts. Nothing shown here is a recommendation to buy or sell.